The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "After Actavis: FTC Update" on January 9, 2014 beginning at 2:00 pm (ET). A panel consisting of Steven Lee of Kenyon & Kenyon LLP, Michael Perry of the Health Care Division of the Bureau of Competition at the Federal Trade Commission, and Bruce Wexler of Paul Hastings LLP will discuss the valuation of reverse payments in general, the role of ancillary agreements such as joint marketing agreements, and whether a branded company's promise not to launch an authorized generic during the generic’s exclusivity period amounts to a reverse payment.
The registration fee for the webinar is $130 (government and academic rates are available upon request). Those interested in registering for the webinar can do so here.
Comments